FINAL ENDURING OUTCOMES REPORT
|
|
- Melina Nash
- 5 years ago
- Views:
Transcription
1 FINAL ENDURING OUTCOMES REPORT OVERVIEW This report summarizes consolidated outcomes data from an enduring satellite symposium activity that was launched In March 2017 and ran for 12 months, cumulatively, ending in March The enduring version of the symposium elucidated new cholesterol practice guidelines focusing on measuring and treating cholesterol and identifying whether someone already has or is at risk for ASCVD and could benefit from treatment (i.e. individualizing treatments). Additional discussion covered emerging data on PCSK9 inhibitors and which population(s) may benefit most from these therapies in the near term. Moreover, stratifying patients by risk allows for appropriate medical therapy (i.e. appropriate drug dosing); therefore, statin intolerance needs to be monitored in patients, and if patients are deemed statin resistant, alternative treatments should be appropriately utilized to mitigate CVD risk. Further discussion hypothesized on potential future areas of research in the hypercholesterolemia disease state, such as the possible role PCSK9 inhibitors and other emerging therapies may play in reducing cardiovascular risk in patients with diabetes. The faculty also discussed anticipated outcomes data from the FOURIER trial (released just after the recording of the enduring content). Certified by the Academy for Continued Healthcare Learning (ACHL) for 1.5 AMA PRA Category 1 Credits Supported by an educational grant from Amgen, Grant ID: GHCCOPS IME 95343
2 Learning Objectives: Upon completion of this activity, participants will be able to: Outline available lipid guidelines and the clinical implications Describe strategies to optimize lipid management in high risk and other groups of patients to appropriately treat/mitigate CVD risk Formulate individual treatment regimens in patients who have not achieved reductions in LDL C levels despite statin therapy Interpret the efficacy and safety data of available and emerging PCSK9 inhibitors and their role in current treatment paradigms Enduring (Final data, 12 months post launch) Total Number of Participants: 3,327 Total Number of Certificates: 1,113 o Met guarantee for minimum number of participants 2000 and 350+ completions EXECUTIVE SUMMARY The enduring activity included a substantial percentage of primary care physicians and nurses, which likely have less direct familiarity with high risk cholesterol management than cardiologists who participated in the activity. However, the primary care and allied health cohort are likely to encounter patients who will require referral to the cardiology cohort and/or may already be on statins or other cholesterol lowering drugs. Level 1 & 2: Faculty were highly rated (3.55 or greater, out of 4.0) across all categories Learners agreed that they were able to achieve the 4 objectives of the course (3.45 mean rating) 95% of learners would recommend this activity to a colleague 88% of learners did not perceive any bias or commercialism towards any product or drug Level 3 & 4: Knowledge increased (or will increase) after participating in the activity according to 72% of learners 60% of participants indicated projected impact of this activity on their performance. This is a relatively high rate of commitment to change practice (Moore s Level 4) given a slower than expected prescribing rate of the PCSK9 inhibitors due to myriad factors (eg, restrictive FDA clinical indication and related payer formulary restrictions, as well as cost). 46% of learners plan to change the management and/or treatment of their patients by considering the use of newly approved drug classes for patients who may not be responding to more traditional therapies. o 25% would create/revise protocols, policies, and/or procedures by more regularly monitoring patient response to LDL C lowering therapies. Reimbursement/insurance issues (26%) was perceived as the largest barriers to change, followed by Cost (22%) Considerations for Future Education (participants were able to choose more than 1 option): Topics of greatest interest to learners for future activities include: o Clinical trial data on emerging agents/therapies (41%) o Practical strategies for managing statin resistant dyslipidemia/familial hypercholesterolemia and related comorbidities (eg, diabetes) (41%) o Medication management in the surgical/interventional setting (28%) Further education is warranted as pre and post test results showed that less than 50% of clinicians correctly answered questions related to: o Current clinical research surrounding dyslipidemia variations by population subset o Emerging areas of research regarding plaque stabilization Continued education on the clinical application of recent outcomes trial data and ensuring access to PCSK9 inhibitors for appropriate patients 2
3 A relatively high self reported bias detection rate of 12% is likely reflective of the broader enduring participant cohort s lower baseline knowledge of PCSK9 inhibitors, since the primary care/allied health cohort typically does not treat these patients. Educational Impact: This activity increased participants knowledge and competence with respect to: o Familiarity with the efficacy and safety profiles associated with FDA approved PCSK9 inhibitors o Therapy intensification, including the use of available PCSK9 inhibitors o The association between LDL C and VLDL and cardiovascular health, as well as genetic variants that may contribute to increased levels of hypercholesterolemia and/or statin resistance o Genetic components of PCSK9 inhibition/lack of inhibition in various populations 3
4 PRE VS POST COMPARISON/INTENT TO CHANGE 1. According to the ARIC study (Atherosclerosis Risk In Communities), 2.6% of African American patients had 28% lower LDL, and a corresponding decreased risk of CVD of what percentage? A. 10% B. 32% C. 25% D. 88% Enduring Pre Vs Post 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 44% 38% 30% 29% 26% 10% 17% 6% A B C D Enduring Pre Enduring Post Pre: N= 1,281 Post: N= 1,113 Analysis: In the enduring activity, the mostly non cardiology learners (primary care physicians, nurses, allied health, and other medical practice specialties) had a low level of baseline knowledge regarding the potential impact of genetic variants of PCSK9. While learners knowledge increased substantially post activity (44% versus 6%, a 633% increase), it still illustrates a need for further education on the impact of genetic variants related to hypocholesterolemia for most clinicians. 2. Learners answered the following question based on Case RK s patient background. Patient History/Background: RK is a 58 year old man who presented with angina 1 year ago and underwent cardiac catheterization that showed 90% proximal LAD stenosis. A drug eluting stent (DES) was implanted successfully. A lifetime nonsmoker, RK s past medical history is significant for type 2 diabetes mellitus and hypertension. Patient Case Question: RK started atorvastatin 80 mg daily on discharge but developed incapacitating myalgias after 2 3 weeks w/o CK elevation. Reversible causes excluded. After improvement of symptoms over 2 3 weeks w/o statin, RK again developed myalgias upon re challenge; now tolerate rosuvastatin 5 mg, 3 days a week. He has been on this dose for 9 months w/o issues. RK returns for a follow up visit and reports feeling well/walking 0.5mile daily. RK s LDL C has dropped from 140 mg/dl a year ago to 100 mg/dl today (28% reduction). TC=175 and non HDL=130 mg/dl. Which of the following is the next BEST course of action? A. He is on maximally tolerated dose of statin and has had a 30% reduction in LDL. Continue this and encourage more intensive lifestyle changes. B. He would benefit from addition of ezetimibe (an intestinal cholesterol absorption blocker) C. He would benefit from addition of niacin 1 gram daily D. He would benefit from addition of fenofibrate because he is diabetic 4
5 Enduring Pre Vs Post 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 97% 59% 27% 9% 1% 1% 5% 1% A B C D Enduring Pre Enduring Post Pre: N= 1,281 Post: N=1,113 Analysis: Learner baseline knowledge on intensification of therapy for this theoretical case patient increased from 59% to 97%. These data may be indicative of the fact that this broad cohort of learners has strong familiarity with common comorbid conditions such as type 2 diabetes mellitus and hypertension. 3. After 3 months of being on rosuvastatin 5 mg 3x/week and ezetimibe 10 mg/d, RK s lipid profile now is: LDL 80 (down from 100), TC 155 and non HDL 110 mg/dl. Which one of the following choices is the next BEST course of action? A. He is on maximally tolerated dose of statin ezetimibe combo and has had a ~ 45% reduction in LDL from baseline. Continue this and encourage more intensive lifestyle changes. B. He would benefit from the addition of a PCSK9 antibody C. He would benefit from the addition of mipomersen (an antisense inhibitor of apob 100 mrna) or lomitapide (a microsomal triglyceride transfer protein inhibitor) D. He is at high risk and would benefit from referral to a lipid specialist for LDL apheresis Enduring Pre Vs Post 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 93% Enduring Pre 47% 36% 12% 4% 1% 5% 2% A B C D Pre: N= 1,281 Post: N= 1,113 Enduring Post Analysis: Baseline knowledge on this question was low, at only 36%, likely an indicator of the mostly non cardiology/primary care practice area of enduring participants. However, performance on this question rose to 93% (a nearly 160% increase), indicating highly effective education for practitioners. 5
6 4. True or False: New research indicates cholesterol lowering drugs reduce clinical events by stabilizing plaques. Correct Answer: True. Enduring Pre Vs Post 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 99% 85% 15% 1% 1 0 TRUE FALSE Enduring Pre Enduring Post Pre: N= 1,281 Post: N= 1,113 Analysis: Primary care and allied health practitioners demonstrated they had a high level of baseline knowledge, 85%, regarding statins mechanisms of action regarding plaques, rising to 99% post test, a 16% increase. 6
7 FINAL ENDURING EVALUATION SUMMARY 1. Evaluate faculty (4=Excellent, 3=Good, 2=Fair, 1=Poor) Ability to effectively convey the subject matter Ability to deliver an objective and balanced presentation Ability to present scientifically rigorous information Expertise on the subject matter Faculty Did you perceive any bias or commercialism towards any product or drug in this activity? A. No 88% B. Yes. If yes, please explain 12% Comments: PCSK9 3. Please evaluate A. Quality of educational content Excellent/Good 95% B. Effectiveness of teaching method used Excellent/Good 93% C. Appropriateness and effectiveness of active learning strategies (questions, cases, discussion, etc) Excellent/Good 93% No. of Respondents
8 4. Learning Objectives (4=Excellent, 3=Good, 2=Fair, 1=Poor) A. Outline available lipid guidelines and the clinical implications 3.45 Rating B. Describe strategies to optimize lipid management in high risk and other groups of patients to appropriately treat/mitigate CVD risk C. Formulate individual treatment regimens in patients who have not achieved reductions in LDL C levels despite statin therapy D. Interpret the efficacy and safety data of available and emerging PCSK9 inhibitors and their role in current treatment paradigms Please rate the importance of your reasons for attending this educational activity A. Topics Extremely/Very Important B. CME/CE credit Extremely/Very Important 92% 93% No. of Respondents Please rate the projected impact of this activity on your knowledge, competence, performance and patients outcomes: This activity increased my knowledge. A. Yes. If yes, please describe: 72% B. No 8% C. No Change 20% 7. This activity increased my competence. A. Yes If yes, please describe: 62% B. No 11% C. No Change 27% 8
9 8. This activity will improve my performance. A. Yes If yes, please describe: 59% B. No 13% C. No Change 28% 9. This activity will improve my patient outcomes. A. Yes. If yes, please describe: 55% B. No 14% C. No Change 31% 10 Please identify how you will change your practice as a result of attending this activity (select all that apply) A. Change the management and/or treatment of my patients by considering the use of newly approved drug classes for patients who may not be responding to more traditional therapies. Please specify: 46% B. Create/revise protocols, policies, and/or procedures by more regularly monitoring patient response to LDL C lowering therapies across various patient subgroups. Please specify: 25% C. This activity validated my current practice; no changes will be made. 37% D. Other Change Please specify: 5% 9
10 11. Please indicate any barriers you perceive in implementing these changes. (check all that apply) A. Cost 22% B. Lack of experience 19% C. Lack of opportunity (patients) 12% D. Lack of resources (equipment) 8% E. Lack of administrative support 14% F. Lack of time to assess/counsel patients 10% G. Reimbursement/insurance issues 26% H. Patient compliance issues 19% I. Lack of consensus or professional guidelines 5% J. No barriers K. Other, please specify: % 2% Comments: Technologist Role Only 12. Number of patients in your care with dyslipidemia: A. 0 16% B % C % D % E. >50 33% 10
11 13. Would you recommend this activity to a colleague? A. Yes 92% B. No 5% No. of Respondents What topic areas would you like to see in future activities? (check all that apply) A. Clinical trial data on emerging agents/therapies 41% B. Practical strategies for managing statin resistant dyslipidemia/familial hypercholesterolemia 41% C. Medication management in the surgical/interventional setting 28% D. Other 2% 15. What is one pearl you took away as a result of your participation? (See Appendix) 16 General Comments (See Appendix) 11
Prevention of HIV-related Cardiovascular Disease: an enewsletter Series
Prevention of HIV-related Cardiovascular Disease: an enewsletter Series Final Outcomes Report Gilead Grant ID: ZZ03-16 Data reflective through October 6, 2017 Series Landing Page Overview Activity: enewsletter
More informationDyslipidemia and Combination Therapy: A Framework for Clinical Decision Making
Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making Shashank Sinha, MD Pamela B. Morris, MD, FACC 8 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO
More informationAdvances in the Multidisciplinary Management of Hepatocellular Carcinoma: Strategies for Incorporating Emerging Immunotherapy Treatment Options
Advances in the Multidisciplinary Management of Hepatocellular Carcinoma: Strategies for Incorporating Emerging Immunotherapy Treatment Options Interim Outcomes Report Merck & Co., Inc. Grant ID: AAN-170919-044712
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationTreating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives
Treating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives Interim Outcomes Report (as of November 20, 2018) Supported by an educational grant from Neurocrine Biosciences Overview Activity
More informationDeep Dive into Contemporary Cholesterol Management. Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City
Deep Dive into Contemporary Cholesterol Management Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO CONSENSUS IN
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationFINAL OUTCOMES REPORT
OVERVIEW FINAL OUTCOMES REPORT The annual Endovascular Advances: A Hands On Preceptorship Program is a continuing medical education series designed to provide physicians with hands on training in all aspects
More informationFINAL OUTCOMES REPORT
OVERVIEW FINAL OUTCOMES REPORT The annual Endovascular Advances: A Hands On Preceptorship Program is a continuing medical education series designed to provide physicians with hands on training in all aspects
More informationFrom Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment
From Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment Final Enduring Outcomes Report Celgene Grant #20502 Janssen Grant #CE15843 Novartis Grant #NGC29612 Reflective of
More informationTargeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions
Targeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions Interim Outcomes Report February 2019 Gilead Sciences, Inc. Grant ID: 02669 Overview Activity Description:
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationCardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationComprehensive Strategies to Improve Clinical Outcomes in Heart Failure. Live and Enduring Interim Outcomes Report. Novartis Grant ID: NGC29501
Comprehensive Strategies to Improve Clinical Outcomes in Heart Failure Live and Enduring Interim Outcomes Report Novartis Grant ID: NGC29501 Program Information Overview This symposium and enduring material
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationPamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCommon Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2
Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia
More informationComprehensive Strategies to Improve Clinical Outcomes in Heart Failure. Live and Enduring Final Outcomes Report. Novartis Grant ID: NGC29501
Comprehensive Strategies to Improve Clinical Outcomes in Heart Failure Live and Enduring Final Outcomes Report Novartis Grant ID: NGC29501 Program Information Overview This symposium and enduring material
More informationDesigning an Electronic Medical Record-based Clinical Decision Support Tool to Improve CVD Screening in Rheumatoid Arthritis Patients
Designing an Electronic Medical Record-based Clinical Decision Support Tool to Improve CVD Screening in Rheumatoid Arthritis Patients Provided and Certified By Grant Award # 045604 Report Date: March 29,
More informationRequest for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax
Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationArthritis: Incorporating
From Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment Interim Outcomes Report Celgene Grant #20502 Janssen Grant #CE15843 Novartis Grant #NGC29612 Reflective of data
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationCoronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)
CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationADMINISTRATIVE POLICY AND PROCEDURE
ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationEVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378
Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 This drug requires a written request for prior authorization. All requests for Repatha (evolocumab) require review by a pharmacist prior
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:
Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017
Clinical Policy: (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationStudy 1 ( ) Pivotal Phase 3 Long-Term Safety Study Top-Line Results
Study 1 (1002-040) Pivotal Phase 3 Long-Term Safety Study Top-Line Results May 2, 2018 1 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE Safe Harbor Forward-Looking Statements These
More informationJuxtapid and Kynamro
DRUG POLICY Juxtapid and Kynamro BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationPrevention Updates and Paradigm Shifts
Prevention Updates and Paradigm Shifts Andrew Freeman, MD, FACC Director of Clinical Cardiology and Operations National Jewish Health Assistant Professor of Medicine National Jewish Health and University
More informationCost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia.
Cost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia. The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ) Following
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More information9th Annual Orange County Symposium on Cardiovascular Disease Prevention
The Division of Cardiology, Department of Medicine, UC Irvine School of Medicine Presents the 9th Annual Orange County Symposium on Cardiovascular Disease Prevention Future Directions in Prevention of
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Repatha) Reference Number: HIM.PA.SP46 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationReducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD
Reducing Cardiovascular Risk Through Non-Statins Kim K. Birtcher, PharmD Joseph Saseen, PharmD Target Audience: Pharmacists ACPE#: 0202-0000-18-049-L01-P Activity Type: Application-based This activity
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationFamilial Hypercholesterolemia
Familial Hypercholesterolemia Dr.Ramzi Al-Mohammadi Assistant Professor of Medicine Interventional Cardiologist, Advanced HF and Transplant Consultant Classification of Hyperlipedemia Primary hyperlipedemia:
More information2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004
Perspectives on the 2013 ACC/AHA Cholesterol Guidelines Donald M. Lloyd-Jones, MD ScM Senior Associate Dean Chair and Professor of Preventive Medicine Northwestern Feinberg School of Medicine Disclosures
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017
Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationCalculating Risk for Primary Prevention of Cardiovascular Disease (CVD)
Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD) 2. Welcome by Stacey Sheridan, MD, MPH Hello. My name is Stacey Sheridan, and I m here as your partner in Heart Health Now. The North
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationDiabetes: A Cardiovascular Disease Current Approaches to Treatment A Continuing Education Program
Diabetes: A Cardiovascular Disease Current Approaches to Treatment A Continuing Education Program Sponsored by: Blue Cross and Blue Shield of New Mexico and New Mexico Health Care Takes On Diabetes Objectives:
More informationObservations on US CVD Prevention Guidelines. Donald M. Lloyd-Jones, MD ScM FACC FAHA
Observations on US CVD Prevention Guidelines Donald M. Lloyd-Jones, MD ScM FACC FAHA What are Guidelines? Evidence Base for Guidelines Tricoci, JAMA 2009 Evidence Base for Guidelines Tricoci, JAMA 2009
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationUPDATES IN LIPID MANAGEMENT
UPDATES IN LIPID 2017 Cardiovascular Symposium MANAGEMENT SUDHA RAVILLA, MD, DIPLOMATE, ABCL MEDICAL DIRECTOR CLINICAL LIPIDOLOGY TMHPP METABOLIC HEALTH CENTER INTRODUCTION CVD is STILL the No. 1 cause
More informationReduced Carbohydrate Intake May Lower Cardiovascular Risk CME
To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/516977 This activity is supported by funding from WebMD. Reduced
More informationACC/AHA Guidelines Bulls-eyes and Misses
ACC/AHA Guidelines Bulls-eyes and Misses James Trippi, MD, FACC Diplomate American Board of Clinical Lipidology Complex Cholesterol Center of St. Vincent Health Indianapolis, IN October 18, 2014 Level
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationLipid Control Today: Management within the Context of other Cardiovascular Risk Factors
Best Practices Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention
More informationReview current guideline recommendations for lipid-lowering therapy
Breakout Session #3 New Paradigms in the Management of Dyslipidemia Review current guideline recommendations for lipid-lowering therapy Dr Meral KAYIKCIOGLU Ege University Medical School, Cardiology Dept,
More information1. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?
09/07/2016 Prior Authorization AETA BETTER HEALTH OF KETUCK (MEDICAID) PCSK9 Inhibitors (K88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationDYSLIPIDEMIA RECOMMENDATIONS
DYSLIPIDEMIA RECOMMENDATIONS Α. DIAGNOSIS Recommendation 1 INITIAL LIPID PROFILING (Level of evidence II) It is recommended to GPs and other PHC Physicians to assess the lipid profile {total cholesterol
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American
More informationClinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationParticipatory Medicine and Diabetes Care: A Clinician and Patient Education Initiative. Final Outcomes Assessment September 2017
Participatory Medicine and Diabetes Care: A Clinician and Patient Education Initiative Final Outcomes Assessment September 2017 Novo Nordisk Grant ID: 019262 CME Activity Page Patient Education Activity
More informationHigh ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/8/2018 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/17, 5/16, 5/15, 2/14, LOB AFFECTED: Medi-Cal
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
More information... CPE/CNE QUIZ... CPE/CNE QUESTIONS
CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date:
Clinical Policy: (Repatha) Reference Number: ERX.SPA.169 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information